Skip to Content

Tag: Diabetes

Specialty Providers

CCS Launches AI-powered model

June 11, 2024HME News Staff

DALLAS – CCS has launched PropheSee, an AI-powered predictive model for healthcare organizations focused on improving adherence in people with diabetes who use a continuous glucose monitoring (CGM) device.  With the deployment of this new predictive model, CCS has observed increases in adherence rates among targeted, high-risk patient cohorts by as much as 50% compared to control groups. The increase in adherence resulted from tech-enabled, personalized interventions based on risk classification,...

Artificial Intelligence (AI), CCS, Diabetes, PropheSee

Read Full Articlered right arrow icon

Bill Mixon

Also Noted

Advanced Diabetes Supply Group supports race for cure 

June 3, 2024HME News Staff

CARLSBAD, Calif. - Advanced Diabetes Supply Group sponsored the American Diabetes Association’s annual Tour de Cure, a cycling event aimed at spreading awareness and raising funds toward a cure for the chronic disease. The company, comprised of ADS and US Med, sponsored the 2024 Tour de Cure: Capital Region ride on June 2 at the Ellms Family Farm in Ballston Spa, N.Y. “We are proud to be sponsors of the 2024 Tour de Cure and show our support in the fight against diabetes,” said...

Advanced Diabetes Supply (ADS), Diabetes, Fundraising

Read Full Articlered right arrow icon


In brief: Dexcom study, test strip fraud, InfuSystem stock buy-back

May 24, 2024HME News Staff

LONDON – Nearly half of patients with Type 2 diabetes were unaware of the disease’s effects, according to a new study from Dexcom.  The “Dexcom State of Type 2 Report,” released in conjunction with the launch of the Dexcom ONE+ continuous glucose monitor, also found:  63% of people with diabetes are encountering difficulties in managing their disease, including challenges related to improving their diet or their mental health; and  42% of...

Dexcom, Diabetes, HealthWell Foundation, InfuSystem, Rehab Medical, ResMed

Read Full Articlered right arrow icon


Quipt makes play for diabetes

May 17, 2024Theresa Flaherty, Managing Editor

CINCINNATI – Quipt Home Medical has dipped its toe into the diabetes market, which company execs say represents a “promising avenue” for growth.  The company started testing the market in fiscal 2023, offering CGMs and supplies in certain markets, CEO Greg Crawford said on a call to discuss second fiscal quarter 2024 earnings.  “The early signs have looked pretty good for us, so now we're in the process of expanding that around the rest of the company,”...

Diabetes, Quipt Home Medical

Read Full Articlered right arrow icon

Also Noted

Insulet reports earnings increase, gains market share

May 15, 2024HME News Staff

ACTON, Mass. – Insulet reported revenue of $441.7 million for the first quarter 2024, an increase of 23.3% compared to the prior year. Total Omnipod revenue was $433.0 million, an increase of 21.1%, with U.S. Omnipod revenue $317.7 million. “We are pleased with our strong first quarter results, which underscore the strength of our advanced technology platform and deep competitive advantages,” said Jim Hollingshead, president and CEO. “During the quarter, we achieved strong...

Diabetes, Insulet, Omnipod

Read Full Articlered right arrow icon


AdaptHealth sees small but positive trends 

May 8, 2024Theresa Flaherty, Managing Editor

PLYMOUTH MEETING, Pa. – AdaptHealth’s diabetes business “outperformed expectations” during the first quarter of 2024 and company execs are cautiously optimistic that their efforts to boost the segment are starting to make headway.  Diabetes revenue was $149.3 million for the quarter, a 2% increase and the first year-over-year increase for the segment since the second quarter of 2023, driven by the company’s moves to double its sales force, name Briah Carey as...

AdaptHealth, Continuous Glucose Monitor (CGM), Diabetes, Financial Results

Read Full Articlered right arrow icon


Health care goes OTC

April 26, 2024Theresa Flaherty, Managing Editor

As is par for the course these days, my inbox this month has been filled with diabetes tech announcements: Edgepark is adding a new insulin delivery system to its portfolio, Insulet’s Omnipod is fueling growth and Ascensia is expanding access to its Eversense device by extending its PASS program, which offers a substantial discount for users.  That last one is key: All the technology in the world won’t help if it’s too expensive for people to acquire. And this stuff is expensive...

Ascensia Diabetes Care, Continuous Glucose Monitor (CGM), Diabetes, Eversense, Omnipod

Read Full Articlered right arrow icon

Also Noted

Ascensia extends PASS program

March 14, 2024HME News Staff

PARSIPPANY, N.J. – Ascensia Diabetes Care and Senseonics Holdings will extend the Eversense Payment Assistance and Simple Savings (PASS) Program. Designed to help people in the U.S. access the Eversense E3 CGM System more affordably, the program offers major savings for eligible individuals looking to experience the unique benefits of the only long-term CGM system available. Eligible individuals will pay only $99 out of pocket for an unlimited number of six-month Eversense E3 systems under...

Ascensia Diabetes Care, Continuous Glucose Monitor (CGM), Diabetes, Eversense, Senseonics

Read Full Articlered right arrow icon

Arti Masturzo

Specialty Providers

CCS ‘on right track’ 

March 13, 2024Theresa Flaherty, Managing Editor

GLP-1 medications misconception: Nearly 60% of diabetes patients surveyed by CCS mistakenly believe that GLP-1 medications alone are a silver bullet for managing their health. However, these drugs need to be integrated into a long-term holistic care plan.  Education and support gap: The survey results highlight a real need for better education and support for patients managing their diabetes. Diabetes suppliers are well-positioned to...

CCS, Coaching, Diabetes, Education, GLP-1

Read Full Articlered right arrow icon


In brief: AAH on cath fraud & CCS on GLP-1s

March 8, 2024HME News Staff

WASHINGTON – AAHomecare has issued a statement affirming its support for the government to implement real-time monitoring of claims to detect potential fraud and abuse, in response to news reports of potential Medicare fraud by a handful of intermittent catheter companies.  AAHomecare's statement, which was shared with CMS and Capitol Hill, also reiterates recommendations for federal government initiatives to better monitor DME supplier billing practices and trends, including:  Increased...

AAHomecare, Catheter, CCS, Diabetes, Noridian, Soleo Health

Read Full Articlered right arrow icon